Clinical trial
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00292981 · CSL Behring, Industry · Completed
Key facts
| NCT number | NCT00292981 |
|---|---|
| Title | C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) |
| Official title | Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks |
| Lead sponsor | CSL Behring, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hereditary Angioedema |
| Intervention type | Drug |
| Interventions | C1 Esterase Inhibitor |
| Enrollment | 57 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Feb 16, 2006 |
| Last update posted | May 7, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: